$SLQT

SelectQuote reported fiscal 2026 revenue of $1.6B, up 6% YoY, with adjusted EBITDA of $109.1M. Healthcare Services revenue grew 14% to $845M. Fiscal 2027 guidance includes revenue of $1.35B-$1.45B and adjusted EBITDA of $90M-$115M. Management highlighted cash flow improvement and debt reduction strategies, noting industry volatility in Medicare Advantage.

SelectQuote (SLQT) reported fiscal 2026 revenue of $1.62B, up 6% YoY, with operating cash flow increasing $44M. However, it posted a Q4 net loss of $16.8M and guided fiscal 2027 revenue lower. Healthcare Services revenue grew 14% to $845M, despite drug pricing changes. The company identified $30M in annual savings from AI tools. Guidance expects fiscal 2027 revenue to decline 14% at the midpoint, with Medicare Advantage policies projected to fall further.

SelectQuote, Inc. reported Q4 2026 earnings, focusing on cash flow and leverage reduction. Healthcare Services became the largest revenue contributor with a $50M EBITDA run rate. Fiscal 2027 revenue is projected to decline 14% due to Medicare Advantage policy drops and the Inflation Reduction Act. Operating cash flow is expected to double to $60M, with free cash flow targeted at $50M. The company plans to reduce debt and invest in technology for efficiency gains.

SelectQuote (SLQT) reported Q4 Healthcare Services membership at 109,000, with expected revenue decline of 10-15% in fiscal 2027 due to the Inflation Reduction Act. Senior segment revenue fell 4% to $576M but maintained 26% EBITDA margins. Life insurance revenue rose 8% to $186M. The company guided fiscal 2027 revenue at $1.35B-$1.45B and adjusted EBITDA at $90M-$115M, with cash flow doubling.

Selectquote (SLQT) shares dropped 16.59% in pre-market trading to $0.643 after missing Q4 2026 earnings and revenue estimates. The company reported a loss of $0.19 per share and $321.7M in revenue, while FY2027 guidance of $1.35B-$1.45B fell below consensus. Analysts had already lowered ratings due to sector headwinds, including Medicare Advantage marketing cuts and reimbursement pressures.

SelectQuote, Inc. (SLQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2026 Results Fourth Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights • Revenue of $321.7 million • Net loss of $(16.8) million • Adjusted EBITDA* of $11.9 million Fiscal Year 2027 Guidance Ranges:

Analysts at Noble Financial and UBS reiterated bullish views on SelectQuote (SLQT) and Nasdaq (NDAQ). Noble’s Michael Kupinski kept a Buy on SLQT with a $5.00 target versus a $0.69 close. UBS’s Alex Kramm kept a Buy on NDAQ with a $120 target versus a $90.42 close. TipRanks consensus targets were also cited.

SelectQuote (SLQT) stock has surged 54% in the last month after Barchart's Trend Seeker issued a "Buy" signal on April 17, despite a 72% loss over the past year. Analysts project significant earnings growth for next year, though current Wall Street sentiment is mixed. The article suggests SLQT as a speculative rebound candidate for investors looking for beaten-down stocks starting to recover.

SelectQuote Inc. (NYSE: SLQT) received a notice from the NYSE due to its common stock trading below $1.00 per share for 30 consecutive trading days. The company has a six-month cure period to regain compliance, needing its stock to close at or above $1.00 with an average closing price of at least $1.00 over the preceding 30 days. Despite the current low stock price and the delisting notice, InvestingPro analysis suggests the stock may be undervalued, and the company recently reported stronger-than-expected Q2 fiscal year 2026 earnings and launched a new franchise model.

SelectQuote (SLQT) has received a notice from the NYSE regarding non-compliance, as its average share price dropped below $1 for 30 consecutive trading days. The company has a six-month window to regain compliance, with management planning to leverage strong recent financial results, including a new $415 million credit facility, to support its position. Spark, TipRanks' AI Analyst, rates SLQT as Neutral, citing improving fundamentals and a constructive earnings outlook, but is tempered by weak technicals and inconsistent cash flow.